The most heralded new class of immuno-oncology drugs are the immune checkpoint inhibitors, but with this excitement, comes a growing need for well-characterized preclinical models.
In this webinar, an evaluation of several syngeneic murine tumor models to antibody-based, immune checkpoint inhibitor therapeutics will be revealed. In addition, findings detailing the benefits of a multidisciplinary approach to cancer immunotherapy efficacy study design and execution will be outlined.